GSE258991 enzalutamide DK1 [Tursiops] 1 v 0 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE258991_enzalutamide_DK1 [Tursiops]_1_v_0_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE258991_enzalutamide_DK1 [Tursiops]_1_v_0_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE258991_enzalutamide_DK1 [Tursiops]_1_v_0_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE258991_enzalutamide_DK1 [Tursiops]_1_v_0_human_up.

Results found

Linked to

 

Label

Description

 

Gene

H2B clustered histone 8

Gene

H2A clustered histone 11

Gene

ribosomal protein SA 2

Gene

H2A clustered histone 4

Gene

protein kinase Y-linked (pseudogene)

Gene

taxilin gamma Y-linked (pseudogene)

Gene

DPPA2 upstream binding RNA

Gene

CDH13 antisense RNA 2

Gene

NR2F1 regulatory antisense RNA 1

Gene

long intergenic non-protein coding RNA 1138

  • Gene

    H2B clustered histone 8


  • Gene

    H2A clustered histone 11


  • Gene

    ribosomal protein SA 2


  • Gene

    H2A clustered histone 4


  • Gene

    protein kinase Y-linked (pseudogene)


  • Gene

    taxilin gamma Y-linked (pseudogene)


  • Gene

    DPPA2 upstream binding RNA


  • Gene

    CDH13 antisense RNA 2


  • Gene

    NR2F1 regulatory antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1138

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.